Could the Hurricane Energy share price be the bargain of the year?

G A Chester weighs up the potential of exciting oil stock Hurricane Energy plc (LON:HUR) and a pharma firm aiming to rise like a phoenix.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s no shortage of loss-making-but-high-potential companies on the stock market. Oil explorers and developers and pharmaceuticals and medical technology firms offer the prospect of particularly big gains for investors who identify the right company at the right price.

Of course, this is easier said than done. For every millionaire-maker there are dozens of duds. Today, I’m weighing up the potential of oil stock Hurricane Energy (LSE: HUR) and pharma player Circassia (LSE: CIR), which released its annual results today.

Collapse

Heavily backed by cornerstone investors Neil Woodford and his protégé at former employer Invesco, Circassia pursued the development of a whole platform of allergy treatments that were said to build immunity quicker than existing remedies and without the risk of anaphylactic shocks. When its lead cat allergy failed a Phase III study, the entire programme collapsed.

At the height of investor confidence, Circassia was a member of the FTSE 250 index, with a share price of 350p and market capitalisation of over £1bn. Today, it’s on the AIM market, its share price is 31.5p (down a little on the back of its results) and its market cap is £118m. Its accounts show an accumulated loss of over half-a-billion quid.

However, it now has a small portfolio of revenue-generating products, including via a commercial collaboration with AstraZeneca, which has also become a 19% shareholder in Circassia. Could the stock be set to rise like a phoenix?

Recovery?

Just over a year ago, I wrote that I wouldn’t touch Circassia with a bargepole, noting also a 5.42% short position in the stock held by hedge fund Mangrove.

Today’s results showed a £37.2m operating loss on revenue of £48.3m. There are signs of promising revenue growth, and with the share price much lower than a year ago, the valuation picture has improved.

However, continued losses are forecast into next decade and Mangrove has maintained its chunky short position. I’m not convinced the risk/reward proposition with Circassia is compelling, and so continue to see it as a stock to avoid at this stage.

Share price to double?

By contrast, when I last wrote about Hurricane Energy (November 2017), I felt its progress to date, potential to become a major player in the West of Shetland region, and share price of 26.75p (market cap £524m) represented an attractive risk/reward proposition. The shares are currently trading at around 47p (market cap £921m), but I continue to see a compelling investment opportunity.

The company is on track to deliver first oil from its 100%-owned Lancaster discovery before the end of June. Planned initial production is 17,000 barrels a day, and management expects to generate over $200m in operating cash flow on a full-year run-rate basis at a $60 a barrel Brent oil price.

Meanwhile, a 50% farm-in to its Warwick and Lincoln fields by Spirit Energy, providing up to $387m, has enabled an acceleration of activity, including the drilling of three wells this year, one of which was spudded last month.

If we see the company successfully executing on this year’s work programme, I think the share price could easily double from its current level. And with total 2P reserves and 2C contingent resources across the asset base standing at 2.3bn barrels net to Hurricane, there’s potential for the value of the company to continue increasing as time goes on.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

3 things investors should consider when building a £10k passive income

Ken Hall looks at three important considerations for investors looking to build a sizeable passive income for a better financial…

Read more »

Investing Articles

Here’s how much I need in a Stocks and Shares ISA to earn £50,000 of passive income a year

Is it realistic to one day generate £50k in dividend income from a Stocks and Shares ISA portfolio? This writer…

Read more »

Investing Articles

Up 124% in a year! But could the IAG share price still soar from here?

Christopher Ruane looks at why the IAG share price has more than doubled in the space of 12 months --…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

The genie’s out the bottle! After the US invests $500bn, are Warren Buffett’s AI fears warranted?

The new Trump administration's going full speed ahead with AI development, bringing to light fears Warren Buffett highlighted almost a…

Read more »

Investing Articles

The Burberry share price soars 15% after today’s results – is there more to come?

Harvey Jones is thrilled by the stellar performance of the Burberry share price this morning. This puts the lid on…

Read more »

Investing Articles

With £5,000 in UK shares, how much passive income could an investor expect?

A big question for UK investors is how much to pump into shares with the aim of achieving meaningful passive…

Read more »

Growth Shares

Greggs shares have tanked over the last 6 months and a broker says it’s time to sell

A City brokerage firm believes that Greggs shares could fall another 17% from here. Should investors give the stock a…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Have I called the BP share price completely wrong?

Harvey Jones has taken advantage of the slump in the BP share price to pile into this FTSE 100 oil…

Read more »